Showing results (61-70 of 105) with videos related to
Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|August 1, 2013
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer StudyJ A Ajani, M Buyse, M Lichinitser, et al.Cancer|August 15, 1995
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD)E Aranda, A Cervantes, J Dorta, et al.Histopathology|April 7, 2005
Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real-time quantitative RT-PCRJ Lacueva, M Perez-Ramos, J L Soto, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 23, 2016
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trialF Longo-Muñoz, G Argiles, J Tabernero, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 4, 2021
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)Mª A Gómez-España, A F Montes, R Garcia-Carbonero, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancerD Isla, R Rosell, J J Sánchez, et al.Toxicology and Applied Pharmacology|July 25, 2022
SNAI1-expressing fibroblasts and derived-extracellular matrix as mediators of drug resistance in colorectal cancer patientsC Galindo-Pumariño, M Collado, M E Castillo, et al.American Journal of Clinical Oncology|April 16, 1998
Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trialA Abad, B Massuti, E Blanco, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 15, 2014
TTD consensus document on the diagnosis and management of exocrine pancreatic cancerM Benavides, A Abad, I Ales, et al.Lancet (London, England)|December 28, 1999
Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study GroupM Porta, N Malats, M Jariod, et al.Pageof 11